ReNeuron Group plc announced the appointment of John Hawkins, ACA, as ReNeuron Board member with immediate effect. The Group announced that Simon Dew will be joining the Executive Team as Chief Business Officer (CBO). Mr. Hawkins joined ReNeuron in October 2014 as Financial Controller and was also appointed Company Secretary in June 2021.

Mr. Hawkins is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs.Mr Hawkins graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant and worked for the initial part of his career. Mr. Dew is a senior healthcare executive with extensive experience in Business Development and Corporate Strategy. His career spans working at SmithKline Beecham, IQVIA, Astellas Pharma, Gyroscope and more recently exosomes company Evox Therapeutics, where he was responsible for leading two transformational partnership deals with global pharmaceutical companies.

Additionally, the Group is making changes to the Executive team. With immediate effect, Dr. Randolph Corteling assumes the role of Chief Scientific Officer (CSO) with Prof. Stefano Pluchino moving to the role of Chair of the Scientific Advisory Board, continuing to combine working with ReNeuron and his academic work in Exosomes and Regenerative Neuroimmunology at the University of Cambridge. Suzanne Hancock, currently Head of Operations, who has worked with the Group since 2017, moves to the position of Chief Operations Officer (COO).

John Michael Hawkins, aged 56, has been a director or partner of 86 Cathedral Road Rtm Company Limited.